Abstract:Intracerebral hemorrhage (ICH) is a devastating disease with high rates of mortality and morbidity. The major risk factors for ICH include chronic arterial hypertension and oral anticoagulation. After the initial hemorrhage, hematoma expansion and perihematoma edema result in secondary brain damage and worsened outcome. A rapid onset of focal neurological deficit with clinical signs of increased intracranial pressure is strongly suggestive of a diagnosis of ICH, although cranial imaging is required to differentiate it from ischemic stroke. ICH is a medical emergency and initial management should focus on urgent stabilization of cardiorespiratory variables and treatment of intracranial complications. More than 90% of patients present with acute hypertension, and there is some evidence that acute arterial blood pressure reduction is safe and associated with slowed hematoma growth and reduced risk of early neurological deterioration. However, early optimism that outcome might be improved by the early administration of recombinant factor VIIa (rFVIIa) has not been substantiated by a large phase III study. ICH is the most feared complication of warfarin anticoagulation, and the need to arrest intracranial bleeding outweighs all other considerations. Treatment options for warfarin reversal include vitamin K, fresh frozen plasma, prothrombin complex concentrates, and rFVIIa. There is no evidence to guide the specific management of antiplatelet therapy-related ICH. With the exceptions of placement of a ventricular drain in patients with hydrocephalus and evacuation of a large posterior fossa hematoma, the timing and nature of other neurosurgical interventions is also controversial. There is substantial evidence that management of patients with ICH in a specialist neurointensive care unit, where treatment is directed toward monitoring and managing cardiorespiratory variables and intracranial pressure, is associated with improved outcomes. Attention must be given to fluid and glycemic management, minimizing the risk of ventilator-acquired pneumonia, fever control, provision of enteral nutrition, and thromboembolic prophylaxis. There is an increasing awareness that aggressive management in the acute phase can translate into improved outcomes after ICH.

Intracerebral Hemorrhage: Blood Components and Neurotoxicity

Magnesium: Pathophysiological mechanisms and potential therapeutic roles in intracerebral hemorrhage

Treatment of Intracerebral Hemorrhage: Current Approaches and Future Directions

Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions

Intracerebral Hemorrhage: A Brief Evidence-Based Review of Common Etiologies, Mechanisms of Secondary Injury, and Medical and Surgical Management

Secondary mechanisms of injury and viable pathophysiological targets in intracerebral hemorrhage

Stem Cell Therapy: A Promising Therapeutic Method for Intracerebral Hemorrhage.

Pathophysiological Mechanisms and Potential Therapeutic Targets in Intracerebral Hemorrhage

Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage

Intracerebral haemorrhage — mechanisms, diagnosis and prospects for treatment and prevention

Intracerebral hemorrhage: an update on diagnosis and treatment

The acute management of intracerebral hemorrhage: a clinical review

Brain edema formation and therapy after intracerebral hemorrhage

Iron and Intracerebral Hemorrhage: From Mechanism to Translation

Iron toxicity in intracerebral hemorrhage: Physiopathological and therapeutic implications

Treatment Strategies to Attenuate Perihematomal Edema in Patients With Intracerebral Hemorrhage

[Acute treatment of intracerebral hemorrhage]

The hallmark and crosstalk of immune cells after intracerebral hemorrhage: Immunotherapy perspectives

Neuroinflammation after Intracerebral Hemorrhage and Potential Therapeutic Targets

[Treatment of intracerebral hemorrhage - An overview]

Mechanism and Therapy of Brain Edema after Intracerebral Hemorrhage.